Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Curr Opin Allergy Clin Immunol. 2016 Aug;16(4):375–382. doi: 10.1097/ACI.0000000000000284

Table 1.

Biologic Agents and Their Targets

Target Treatment Stage of Development
IgE Omalizumab Marketed
IL-5 Mepolizumab
Reslizumab
Marketed
IL-5R Benralizumab Phase III
IL-4Rα (IL-4/IL-13) Dupilumab
Pitrakinra
Phase III
Phase II
IL-13 Lebrikizumab
Tralokinumab
Phase III
Phase III
IL-17 Secukinumab
Brodalumab
Phase II
Phase II